Immunothrombosis and COVID-19-a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLIMA, Clarice Antunes de
dc.contributor.authorGONCALVES, Fabio Augusto Rodrigues
dc.contributor.authorBESEN, Bruno Adler Maccagnan Pinheiro
dc.contributor.authorPEREIRA, Antonio Jose Rodrigues
dc.contributor.authorPERAZZIO, Sandro Felix
dc.contributor.authorTRINDADE, Evelinda Marramon
dc.contributor.authorFONSECA, Luiz Augusto Marcondes
dc.contributor.authorSUMITA, Nairo Massakazu
dc.contributor.authorPINTO, Vanusa Barbosa
dc.contributor.authorDUARTE, Alberto Jose da Silva
dc.contributor.authorMANIN, Carolina Broco
dc.contributor.authorLICHTENSTEIN, Arnaldo
dc.date.accessioned2023-08-16T18:02:53Z
dc.date.available2023-08-16T18:02:53Z
dc.date.issued2023
dc.description.abstractObjective: COVID-19 is associated with an elevated risk of thromboembolism and excess mortality. Difficulties with best anticoagulation practices and their implementation motivated the current analysis of COVID-19 patients who developed Venous Thromboembolism (VTE). Method: This is a post-hoc analysis of a COVID-19 cohort, described in an economic study already published. The authors analyzed a subset of patients with confirmed VTE. We described the characteristics of the cohort, such as demographics, clinical status, and laboratory results. We tested differences amid two subgroups of patients, those with VTE or not, with the competitive risk Fine and Gray model. Results: Out of 3186 adult patients with COVID-19, 245 (7.7%) were diagnosed with VTE, 174 (5.4%) of them dur-ing admission to the hospital. Four (2.3% of these 174) did not receive prophylactic anticoagulation and 19 (11%) discontinued anticoagulation for at least 3 days, resulting in 170 analyzed. During the first week of hospitaliza-tion, the laboratory most altered results were C-reactive protein and D-dimer. Patients with VTE were more criti-cal, had a higher mortality rate, worse SOFA score, and, on average, 50% longer hospital stay. Conclusion: Proven VTE incidence in this severe COVID-19 cohort was 7.7%, despite 87% of them complying completely with VTE prophylaxis. The clinician must be aware of the diagnosis of VTE in COVID-19, even in patients receiving proper prophylaxis.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationCLINICS, v.78, article ID 100178, 7p, 2023
dc.identifier.doi10.1016/j.clinsp.2023.100178
dc.identifier.eissn1980-5322
dc.identifier.issn1807-5932
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/54807
dc.language.isoeng
dc.publisherELSEVIER ESPANAeng
dc.relation.ispartofClinics
dc.rightsopenAccesseng
dc.rights.holderCopyright ELSEVIER ESPANAeng
dc.subjectCOVID-19eng
dc.subjectBiomarkerseng
dc.subjectCohort studieseng
dc.subjectVenous thromboembolismeng
dc.subjectImmunothrombosiseng
dc.subject.otherdeep-vein thrombosiseng
dc.subject.othervenous thromboembolismeng
dc.subject.otherenoxaparineng
dc.subject.otherinfectioneng
dc.subject.otherriskeng
dc.subject.wosMedicine, General & Internaleng
dc.titleImmunothrombosis and COVID-19-a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospitaleng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcCLARICE ANTUNES DE LIMA
hcfmusp.contributor.author-fmusphcFABIO AUGUSTO RODRIGUES GONCALVES
hcfmusp.contributor.author-fmusphcBRUNO ADLER MACCAGNAN PINHEIRO BESEN
hcfmusp.contributor.author-fmusphcANTONIO JOSE RODRIGUES PEREIRA
hcfmusp.contributor.author-fmusphcSANDRO FELIX PERAZZIO
hcfmusp.contributor.author-fmusphcEVELINDA MARRAMON TRINDADE
hcfmusp.contributor.author-fmusphcLUIZ AUGUSTO MARCONDES FONSECA
hcfmusp.contributor.author-fmusphcNAIRO MASSAKAZU SUMITA
hcfmusp.contributor.author-fmusphcVANUSA BARBOSA PINTO
hcfmusp.contributor.author-fmusphcALBERTO JOSE DA SILVA DUARTE
hcfmusp.contributor.author-fmusphcCAROLINA BROCO MANIN
hcfmusp.contributor.author-fmusphcARNALDO LICHTENSTEIN
hcfmusp.description.articlenumber100178
hcfmusp.description.volume78
hcfmusp.origemWOS
hcfmusp.origem.pubmed37187129
hcfmusp.origem.scieloSCIELO:S1807-59322023000100241
hcfmusp.origem.scopus2-s2.0-85159076806
hcfmusp.origem.wosWOS:001007491300001
hcfmusp.publisher.cityMADRIDeng
hcfmusp.publisher.countrySPAINeng
hcfmusp.relation.referenceAckermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432eng
hcfmusp.relation.referenceAgarwal G, 2022, THER ADV CARDIO DIS, V16, DOI 10.1177/17539447221105013eng
hcfmusp.relation.referenceANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933eng
hcfmusp.relation.referenceBurn E, 2022, LANCET INFECT DIS, V22, P1142, DOI 10.1016/S1473-3099(22)00223-7eng
hcfmusp.relation.referenceCastillo-Perez M, 2021, THROMB J, V19, DOI 10.1186/s12959-021-00346-yeng
hcfmusp.relation.referenceClayton TC, 2011, INT J EPIDEMIOL, V40, P819, DOI 10.1093/ije/dyr012eng
hcfmusp.relation.referenceColeman JJ, 2013, INT J QUAL HEALTH C, V25, P564, DOI 10.1093/intqhc/mzt044eng
hcfmusp.relation.referenceCouturaud F, 2002, BLOOD COAGUL FIBRIN, V13, P241, DOI 10.1097/00001721-200204000-00010eng
hcfmusp.relation.referenceFrantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002eng
hcfmusp.relation.referenceGaertner F, 2016, SEMIN IMMUNOL, V28, P561, DOI 10.1016/j.smim.2016.10.010eng
hcfmusp.relation.referenceGoligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMoa2103417]eng
hcfmusp.relation.referenceGonc alves FAR, 2021, CLINICS, V76, P3547eng
hcfmusp.relation.referenceJenner WJ, 2021, J THROMB THROMBOLYS, V51, P595, DOI 10.1007/s11239-021-02394-7eng
hcfmusp.relation.referenceKyriakoulis KG, 2022, CURR VASC PHARMACOL, V20, P96, DOI 10.2174/1570161119666210824160332eng
hcfmusp.relation.referenceLambden S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2663-7eng
hcfmusp.relation.referenceLAWLER PR, 2021, THERAPEUTIC ANTICOAG, DOI 10.1056/NEJMOA2105911eng
hcfmusp.relation.referenceLazaridis D, 2022, J PHARM PRACT, V35, P1000, DOI 10.1177/08971900211015055eng
hcfmusp.relation.referenceLodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024eng
hcfmusp.relation.referenceLouis SG, 2014, JAMA SURG, V149, P365, DOI 10.1001/jamasurg.2013.3963eng
hcfmusp.relation.referenceMai V, 2021, VASC PHARMACOL, V139, DOI 10.1016/j.vph.2021.106882eng
hcfmusp.relation.referenceManne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214eng
hcfmusp.relation.referenceMiethke-Morais A, 2021, BRAZ J INFECT DIS, V25, DOI 10.1016/j.bjid.2021.101609eng
hcfmusp.relation.referenceMohamed MFH, 2021, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.598846eng
hcfmusp.relation.referenceNakanishi T, 2021, J CLIN INVEST, V131, DOI [10.1172/JCI152386, 10.1101/2021.03.07.21252875]eng
hcfmusp.relation.referenceNopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439eng
hcfmusp.relation.referenceParanjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001eng
hcfmusp.relation.referenceR Core Team, 2020, R LANG ENV STAT COMPeng
hcfmusp.relation.referenceRibeiro DD, 2012, J THROMB HAEMOST, V10, P1179, DOI 10.1111/j.1538-7836.2012.04732.xeng
hcfmusp.relation.referenceSamama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103eng
hcfmusp.relation.referenceSignorelli C, 2020, INT J PUBLIC HEALTH, V65, P1435, DOI 10.1007/s00038-020-01486-0eng
hcfmusp.relation.referenceStrekerud Finn, 1998, Tidsskrift for den Norske Laegeforening, V118, P3934eng
hcfmusp.relation.referenceTan BK, 2021, THORAX, V76, P970, DOI 10.1136/thoraxjnl-2020-215383eng
hcfmusp.relation.referenceTang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768eng
hcfmusp.relation.referenceTromboembolismo Venoso., 2009, REV ASS ME DICA BRAS, V55, P102eng
hcfmusp.relation.referencevon Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120eng
hcfmusp.relation.referenceYu YA, 2020, ANN PALLIAT MED, V9, P1257, DOI 10.21037/apm.2020.04.05eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication856058cb-6fff-4ad6-9fd5-cce7c14410df
relation.isAuthorOfPublicationd99f28de-8606-4d45-b3ee-599bb4568353
relation.isAuthorOfPublication7e0d0193-2d08-40ac-a28d-207578cc316c
relation.isAuthorOfPublicationfc7da293-686f-4b3d-86cc-a36f178ab220
relation.isAuthorOfPublicationb0ea6fff-8a2e-4eb9-b648-e71a8e6e9c84
relation.isAuthorOfPublication26a84314-8c29-427d-b385-f6a8f299ed6e
relation.isAuthorOfPublicatione3cb5925-7539-4ac9-aae8-04df78bc1048
relation.isAuthorOfPublication1cd1f855-03c6-4f9d-9a56-736a59ca3862
relation.isAuthorOfPublication6753819a-cac8-40f0-a177-4d971d93d80f
relation.isAuthorOfPublication8e4f2c15-06a5-444b-826d-84576403144e
relation.isAuthorOfPublicationfa44b19e-812c-44d9-ae50-3ba2c5e8ed1a
relation.isAuthorOfPublication43e02ea2-0950-43d6-848f-4cc8e137367e
relation.isAuthorOfPublication.latestForDiscovery856058cb-6fff-4ad6-9fd5-cce7c14410df
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_LIMA_Immunothrombosis_and_COVID19a_nested_posthoc_analysis_from_a_2023.PDF
Tamanho:
791.72 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/11
Carregar mais